Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Business Wire
Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 millionVolixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD’s The Liver Meeting® 2024PDUFA date for chenodiol in CTX is December 28, 2024In-licensed global rights to PDE4D inhibitor MRM-3379Conference call to provide business updates today, November 12 at 5:30 a.m. PT/8:30 a.m. ET FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2024 and provided a business update.“The Mirum team executed across all aspects of the business in the third quarter with growth across all three commercial medicines highlighted by acceleration of LIVMARLI PFIC sales,” said Chris Peetz, chief executive officer of Mirum. “We also made noteworthy progress on the clinical pipeline with the granting of breakthrough de
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $66.00 price target on the stock.MarketBeat
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc. from $65.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at Robert W. Baird from $44.00 to $50.00. They now have an "outperform" rating on the stock.MarketBeat
- Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
MIRM
Earnings
- 11/12/24 - Beat
MIRM
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- MIRM's page on the SEC website